CLAIMS

1. An isolated antibody specifically binding human CCL17 comprising a heavy chain variable region (VH), a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions (HCDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) and the VL comprises light chain complementarity determining regions (LCDR) 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3), wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of:
   a) SEQ ID NOs: 4, 5, 6, 8, 20 and 28, respectively;
   b) SEQ ID NOs: 4, 5, 6, 9, 21 and 29, respectively;
   c) SEQ ID NOs: 4, 5, 6, 10, 22 and 30, respectively;
   d) SEQ ID NOs: 4, 5, 6, 13, 21 and 33, respectively;
   e) SEQ ID NOs: 4, 5, 6, 14, 20 and 34, respectively;
   f) SEQ ID NOs: 4, 5, 6, 15, 25 and 35, respectively;
   g) SEQ ID NOs: 4, 5, 6, 17, 25 and 37, respectively;
   h) SEQ ID NOs: 4, 5, 6, 18, 26 and 38, respectively;
   i) SEQ ID NOs: 4, 5, 42, 8, 24 and 28, respectively; or
   j) SEQ ID NOs: 4, 5, 43, 8, 24 and 28, respectively.
2. The antibody of claim 1, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 4, 5, 42, 8, 24, and 28, respectively.
3. The antibody of claim 1 or 2, wherein the VH comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 46 and the VL comprises an amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 62.
4. The antibody of any one of claims 1-3, wherein the VH comprises the amino acid sequence of SEQ ID NO: 45, 46, or 47.
5. The antibody of any one of claims 1-4, wherein the VL comprises the amino acid sequence of SEQ ID NO: 50, 51, 52, 55, 56, 57, 59, 60, or 62.

6. The antibody of any one of claims 1-5, wherein the VH and VL comprise the amino acid sequences of:
   a) SEQ ID NOs: 45 and 50, respectively;
   b) SEQ ID NOs: 45 and 51, respectively;
   c) SEQ ID NOs: 45 and 52, respectively;
   d) SEQ ID NOs: 45 and 55, respectively;
   e) SEQ ID NOs: 45 and 56, respectively;
   f) SEQ ID NOs: 45 and 57, respectively;
   g) SEQ ID NOs: 45 and 59, respectively;
   h) SEQ ID NOs: 45 and 60, respectively;
   i) SEQ ID NOs: 46 and 62, respectively; or
   j) SEQ ID NOs: 47 and 62, respectively.
7. The antibody of any one of claims 1-6, wherein the VH and VL comprise the amino acid sequences of SEQ ID NOs: 46 and 62, respectively.
8. The antibody of any one of claims 1-7, wherein the antibody binds human CCL17 at least within CCL17 amino acid residues 21-23, 44-45 and 60-68 of SEQ ID NO: 1.
9. The antibody of claim 8, wherein the antibody binds human CCL17 at least at residues R22 and K23 of SEQ ID NO: 1.
10. The antibody of any one of claims 1-9, wherein the antibody blocks CCL17/CCR4 interaction.
11. The antibody of any one of claims 1-10, wherein the antibody binds human CCL17 with an affinity constant (K_D) of about $1x10^{-10}$ M or less, when the K_D is measured using solution equilibrium affinity in tris-based saline buffer containing 0.05% Tween-20 after co-incubation of the antibody and human CCL17 for 48 hours at 4°C.
12. The antibody of claim 11, wherein the antibody binds human CCL17 with the K_D of about $5x10^{-12}$ M or less.
13. The antibody of any one of claims 1-12, wherein the antibody binds *Macaca fascicularis* (cyno) CCL17 with an affinity constant (K_D) of about $1x10^{-8}$ M or less, when the K_D is measured using solution equilibrium affinity in tris-based saline buffer containing

0.05% Tween-20 after co-incubation of the antibody and cyno CCL17 for 48 hours at 4°C.

14. The antibody of any one of claims 1-13, wherein the antibody inhibits 10 ng/ml human CCL17-induced calcium mobilization in CCRF-CEM cells measured using Fluo-8 NW with an IC_{50} value of about $1x10^{-9}$ M or less.

15. The antibody of claims 1-14, wherein the antibody is human or humanized.

16. The antibody of claim 15, wherein the antibody is of IgG1, IgG2, IgG3, or IgG4 isotype.

17. The antibody of claim 16, wherein the antibody comprises a substitution in an Fc region.

18. The antibody of claim 17, wherein the substitution comprises V234A, G237A, P238S, H268A, V309L, A330S or P331S substitution on IgG2, or S228P, L234A or L235A substitution on IgG4, wherein residue numbering is according to the EU Index.

19. The antibody of claim 18, wherein the substitution comprises V234A/G237A/P238S/H268A/V309L/A330S/P331S substitution on IgG2 or S228P/L234A/L235A substitution on IgG4, wherein residue numbering is according to the EU Index.

20. A pharmaceutical composition comprising the antibody of claims 1-19 and a pharmaceutically accepted carrier.

21. An isolated polynucleotide encoding the VH and/or VL of the antibody of any one of the claims 1-19.

22. A vector comprising the polynucleotide of claim 21.

23. A host cell comprising the vector of claim 22.

24. A method of producing an antibody, comprising culturing the host cell of claim 23 in conditions that the antibody is produced.

25. The use of the antibody of claims 1-19 in the manufacture of a medicament for the treatment of a CCL17-mediated disease.

26. The use of claim 25, wherein the CCL17-mediated disease is an inflammatory disease.

27. The use of claim 26, wherein the inflammatory disease is asthma, ulcerative colitis (UC), atopic dermatitis (AD) or idiopathic pulmonary fibrosis (IPF).
28. The use of the antibody of claims 1-19 in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of asthma or airway hyper-reactivity.
29. The antibody of claims 1-19 for use in therapy.
30. The antibody of claims 1-19 for use in the treatment of a CCL17-mediated disease.
31. The antibody for use according to claim 30, wherein the CCL17-mediated disease is an inflammatory disease, asthma, ulcerative colitis (UC), atopic dermatitis (AD) or idiopathic pulmonary fibrosis (IPF).
32. The antibody for use according to claim 31, wherein the CCL17-mediated disease is asthma.